Skip to main content
. 2023 May 3;19(1):2198467. doi: 10.1080/21645515.2023.2198467

Table 3.

Numbers of DC-ATA products injected by clinical trial. Numbers reported are the average numbers of cells injected during each of the first three injections.

Trial # patients Median # cells injected
x 106
Mean # cells injected
x 106 ± standard deviation
Lowest # cells injected
x 106
Highest # cells injected
x 106
Renal Cell 9 12.8 14.9 ± 7.4 6.0 28.2
Melanoma 54 15.0 15.4 ± 6.4 4.8 33.1
Melanoma 18 13.0 12.5 ± 3.7 5.7 19.1
Hepatoma 8 6.6 8.6 ± 4.5 4.4 16.0
Ovary 28 7.0 10.7 ± 9.0 0.52 29.0
GBM 57 8.5 10.3 ± 7.8 0.27 27.0